PURPOSE: We investigated retrospectively the clinical outcomes of the patients with type iii inflammatory chronic prostatitis, who were treated with fluoroquinolones with and without an α-blocker between 2009-2011.
MATERIAL AND METHODS: Diagnosis was established with medical history (symptoms presented longer than 3 months within previous 6 months), physical examination, Meares-Stamey test and the questionnaire of the NIH-CPSI. The responses to the treatment were assessed with uroflowmetry test and the questionnaire of NIH-CPSI at initial and after 4 weeks of the treatment. The patients with incomplete data and treatment and who treated with α-blockers and/or antibiotics in the period 4 weeks prior to the therapy started in our clinic and had any surgery of lower urinary tract previously were excluded. The patients were classified under 6 groups; group1=ciprofloxacin, group2=ofloxacin, group3=levofloxacin, group4=ciprofloxacin+tamsulosin, group5=ofloxacin+tamsulosin, group 6=levofloxacin+tamsulosin. Wilcoxon Signed Ranks and Kruskal Wallis test were used for comparison of results. Mann Whitney U test with Bonferroni correction made was used as posthoc (P< .05).
RESULTS: The median scores of NIH-CPSI decreased significantly in all groups (P< .05). Levofloxacin reduced the median total scores of NIH-CPSI more than ciprofloxacin and ofloxacin monotherapies. The combination therapies were better than antibiotic therapies alone and best result was obtained in levofloxacin+tamsulosin combination.
CONCLUSION: Tamsulosin+fluoroquinolone (especially tamsulosin+levofloxacin) combinations yielded better results in both NIH-CPSI scores and peak flow rates.
Written by:
Altintas R, Oguz F, Beytur A, Ediz C, Gunes A, Ozer A. Are you the author?
Department of Urology, Medical Faculty, Inonu University, Malatya, Turquía.
Reference: Actas Urol Esp. 2013 Jun 12. pii: S0210-4806(13)00154-X.
doi: 10.1016/j.acuro.2012.11.018
PubMed Abstract
PMID: 23768504
Article in English, Spanish.
UroToday.com Prostatitis Section
